Drug Profile
Izuralimab - Xencor
Alternative Names: PD-1 x ICOS; XmAb-104; XmAb-23104Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Sarcoma; Solid tumours
Most Recent Events
- 07 Nov 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
- 07 Nov 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in USA (IV)
- 07 Nov 2023 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)